Literature DB >> 28069606

Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.

Ivan Ivanov1, Anton Matafonov1,2, Mao-Fu Sun1, Qiufang Cheng1, S Kent Dickeson1, Ingrid M Verhamme1, Jonas Emsley3, David Gailani1.   

Abstract

When blood is exposed to variety of artificial surfaces and biologic substances, the plasma proteins factor XII (FXII) and prekallikrein undergo reciprocal proteolytic conversion to the proteases αFXIIa and α-kallikrein by a process called contact activation. These enzymes contribute to host-defense responses including coagulation, inflammation, and fibrinolysis. The initiating event in contact activation is debated. To test the hypothesis that single-chain FXII expresses activity that could initiate contact activation, we prepared human FXII variants lacking the Arg353 cleavage site required for conversion to αFXIIa (FXII-R353A), or lacking the 3 known cleavage sites at Arg334, Arg343, and Arg353 (FXII-T, for "triple" mutant), and compared their properties to wild-type αFXIIa. In the absence of a surface, FXII-R353A and FXII-T activate prekallikrein and cleave the tripeptide S-2302, demonstrating proteolytic activity. The activity is several orders of magnitude weaker than that of αFXIIa. Polyphosphate, an inducer of contact activation, enhances PK activation by FXII-T, and facilitates FXII-T activation of FXII and FXI. In plasma, FXII-T and FXII-R353A, but not FXII lacking the active site serine residue (FXII-S544A), shortened the clotting time of FXII-deficient plasma and enhanced thrombin generation in a surface-dependent manner. The effect was not as strong as for wild-type FXII. Our results support a model for induction of contact activation in which activity intrinsic to single-chain FXII initiates αFXIIa and α-kallikrein formation on a surface. αFXIIa, with support from α-kallikrein, subsequently accelerates contact activation and is responsible for the full procoagulant activity of FXII.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28069606      PMCID: PMC5356457          DOI: 10.1182/blood-2016-10-744110

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

Authors:  E W DAVIE; O D RATNOFF
Journal:  Science       Date:  1964-09-18       Impact factor: 47.728

2.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

3.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

4.  Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa.

Authors:  D E Cool; C J Edgell; G V Louie; M J Zoller; G D Brayer; R T MacGillivray
Journal:  J Biol Chem       Date:  1985-11-05       Impact factor: 5.157

Review 5.  Medical device-induced thrombosis: what causes it and how can we prevent it?

Authors:  I H Jaffer; J C Fredenburgh; J Hirsh; J I Weitz
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

6.  Polyphosphate exerts differential effects on blood clotting, depending on polymer size.

Authors:  Stephanie A Smith; Sharon H Choi; Rebecca Davis-Harrison; Jillian Huyck; John Boettcher; Chad M Rienstra; Chad M Reinstra; James H Morrissey
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

Review 7.  Factor XII: form determines function.

Authors:  S de Maat; C Maas
Journal:  J Thromb Haemost       Date:  2016-08-02       Impact factor: 5.824

8.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

9.  Coagulation factor XII protease domain crystal structure.

Authors:  M Pathak; P Wilmann; J Awford; C Li; B K Hamad; P M Fischer; I Dreveny; L V Dekker; J Emsley
Journal:  J Thromb Haemost       Date:  2015-03-11       Impact factor: 5.824

10.  Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.

Authors:  Linda Labberton; Ellinor Kenne; Andy T Long; Katrin F Nickel; Antonio Di Gennaro; Rachel A Rigg; James S Hernandez; Lynn Butler; Coen Maas; Evi X Stavrou; Thomas Renné
Journal:  Nat Commun       Date:  2016-09-06       Impact factor: 14.919

View more
  36 in total

1.  Evaluation of the Effect of Crosslinking Method of Poly(Vinyl Alcohol) Hydrogels on Thrombogenicity.

Authors:  Novella M Bates; Cristina Puy; Patrick L Jurney; Owen J T McCarty; Monica T Hinds
Journal:  Cardiovasc Eng Technol       Date:  2020-06-30       Impact factor: 2.495

2.  The hereditary angioedema syndromes.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

3.  The evolution of factor XI and the kallikrein-kinin system.

Authors:  Michał B Ponczek; Aleksandr Shamanaev; Alec LaPlace; S Kent Dickeson; Priyanka Srivastava; Mao-Fu Sun; Andras Gruber; Christian Kastrup; Jonas Emsley; David Gailani
Journal:  Blood Adv       Date:  2020-12-22

Review 4.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

5.  In vivo and in vitro effects on cholinesterase of blood of Oreochromis mossambicus by copper.

Authors:  Ain Aqilah Basirun; Siti Aqlima Ahmad; Mohd Khalizan Sabullah; Nur Adeela Yasid; Hassan Mohd Daud; Ariff Khalid; Mohd Yunus Shukor
Journal:  3 Biotech       Date:  2019-02-02       Impact factor: 2.406

Review 6.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

Review 7.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

8.  The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome.

Authors:  Eliza Ruben; William Planer; Mathivanan Chinnaraj; Zhiwei Chen; Xiaobing Zuo; Vittorio Pengo; Vincenzo De Filippis; Ravi K Alluri; Keith R McCrae; Paolo Macor; Francesco Tedesco; Nicola Pozzi
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

9.  Cationic zinc is required for factor XII recruitment and activation by stimulated platelets and for thrombus formation in vivo.

Authors:  Sharjeel A Chaudhry; Matthew Serrata; Lindsay Tomczak; Sarah Higgins; Justine Ryu; Dylan Laprise; Keiichi Enjyoji; Roelof Bekendam; Virendar Kaushik; Robert Flaumenhaft; Pavan K Bendapudi
Journal:  J Thromb Haemost       Date:  2020-07-30       Impact factor: 5.824

Review 10.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.